Ascendis Pharma A/S
ASND
$191.08
-$4.90-2.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 55.71% | -142.84% | 62.40% | 7.37% | 17.24% |
| Total Depreciation and Amortization | 2.22% | 11.95% | -11.15% | 1.81% | -2.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 199.70% | -58.78% | 237.75% | -174.12% | -29.88% |
| Change in Net Operating Assets | -193.97% | 143.36% | -235.62% | 633.75% | 73.67% |
| Cash from Operations | 44.69% | 83.79% | -50.59% | 6.48% | 40.16% |
| Capital Expenditure | -565.49% | -65.65% | 13.01% | -39.47% | -70.42% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -100.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 194.19% | -- | -100.00% |
| Cash from Investing | -565.49% | -80.75% | 25.99% | -184.50% | -91.58% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -78.96% | -4.04% | -4.80% | 0.28% | -1.22% |
| Issuance of Common Stock | -9.87% | -38.03% | -92.47% | 81,140.55% | -98.28% |
| Repurchase of Common Stock | 100.00% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 141.77% | -20,561.17% | -99.98% | 17,901.79% | -113.21% |
| Foreign Exchange rate Adjustments | -141.07% | -139.40% | 571.56% | -380.12% | -60.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 38.13% | 37.72% | -117.44% | 708.80% | 15.16% |